Similarly, a higher proportion of patients who received earlier-line abatacept were in SDAI and CDAI LDA and/or remission compared with patients who received abatacept as a later-line biologic with RF/ACPA double-negative RA. The gene discussed is PRTN3; the disease is rheumatoid arthritis.